Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus

Key facts

Sponsor

Sarepta Therapeutics, Inc.

Principal Investigator

Alison Heald, MD

Sarepta Therapeutics, Inc.

Intervention

AVI-6003(drug)

Enrollment

30 enrolled

Eligibility

18-50 years · All sexes

Timeline

2011 – 2011

Study locations (1)

• West Coast Clinical Trials, Cypress, California, United States

Collaborators

United States Department of Defense

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Marburg hemorrhagic fever

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT06620003
  A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Marburg Virus Vaccine in Healthy Adults
  Albert B. Sabin Vaccine Institute

See all trials for Marburg hemorrhagic fever →